Physician profile
Patrick T Murray
NPI 1871971705
$4,515.77
in general payments reported to CMS, 2019-2025
31 companies · $45.30 in 2025
The $45.30 reported for 2025 was less than what a typical Sports Medicine (Family Medicine) provider received nationally (typical 2025 total: $113).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,547 · 2020: $687 · 2021: $730 · 2022: $337 · 2023: $126 · 2024: $43.60 · 2025: $45.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $215.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $2,017.00 | 2019 | |
| Lilly USA, LLC | $389.52 | 2019-2023 | Jardiance, Emgality, Mounjaro |
| Pfizer INC. | $337.76 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $314.25 | 2019-2022 | |
| Novo Nordisk INC | $281.31 | 2019-2024 | Rybelsus, Ozempic |
| Biohaven Pharmaceuticals, INC. | $184.63 | 2021 | |
| Sunovion Pharmaceuticals INC. | $124.13 | 2019 | |
| Merck Sharp & Dohme LLC | $95.25 | 2019 | |
| Abbvie INC. | $83.43 | 2021-2022 | |
| Astellas Pharma US INC | $73.90 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.96 | 2019-2022 | |
| Amarin Pharma, INC. | $58.29 | 2019-2020 | |
| Exact Sciences Corporation | $51.86 | 2023-2025 | Cologuard Collection Kit |
| Allergan, INC. | $43.14 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.69 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $31.33 | 2019-2024 | Repatha |
| Glaxosmithkline, LLC. | $29.21 | 2019-2021 | |
| Dynavax Technologies Corporation | $28.96 | 2025 | Heplisav-B |
| Ibsa Pharma INC. | $28.23 | 2020 | |
| Fidia Pharma USA INC. | $26.96 | 2020-2023 | Hym/Hyn |
| Bioventus LLC | $23.55 | 2022 | |
| Daiichi Sankyo INC. | $21.25 | 2020 | |
| Pacira Therapeutics, INC. | $19.68 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.66 | 2023 | Xifaxan |
| Currax Pharmaceuticals LLC | $18.14 | 2020 | |
| Dermira, INC. | $17.90 | 2020 | |
| Novartis Pharmaceuticals Corporation | $17.31 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.89 | 2022 | |
| Sanofi-Aventis U.S. LLC | $16.67 | 2019 | |
| Dexcom, INC. | $15.19 | 2022 | |
| Metuchen Pharmaceuticals | $14.72 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Murray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.